Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 19 of 782 for:    Smoking: Clinical Trials

Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Centre for Addiction and Mental Health
Sponsor:
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
John Cunningham, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier:
NCT01429129
First received: September 2, 2011
Last updated: June 5, 2014
Last verified: June 2014
  Purpose

This study will examine the efficacy of mailed distribution of free Nicotine Replacement Therapy to smokers. Telephone numbers will be randomly selected from across Canada in order to recruit adult smokers interested in completing a smoking survey and willing to be interviewed again in 8 weeks and 6 months time. Study participants will be asked about their smoking history and a hypothetical question: would they be interested in receiving the nicotine patch if this were to be provided to them free of charge? Participants expressing interest will be randomly assigned to one of two groups. One group will be offered the opportunity to actually receive a program of 5 weeks of the nicotine patch for free right away and the other group will not be offered the free nicotine patches. The proportions of smokers in the two groups who quit smoking by the 6-month interview will be compared.


Condition Intervention Phase
Smoking
Drug: Nicotine replacement therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers

Resource links provided by NLM:


Further study details as provided by Centre for Addiction and Mental Health:

Primary Outcome Measures:
  • Smoking cessation [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Smoking cessation [ Time Frame: 8 week follow-up ] [ Designated as safety issue: No ]
  • Reduction in smoking since baseline [ Time Frame: past 6 months ] [ Designated as safety issue: No ]
  • Compliance with course of nicotine patches provided [ Time Frame: past 6 months ] [ Designated as safety issue: No ]
  • Purchase and use of NRT and smoking cessation aids [ Time Frame: past 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 1000
Study Start Date: May 2012
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nicotine Replacement Therapy Drug: Nicotine replacement therapy
Nicotine transdermal patches as per product monograph
Other Name: Nicoderm
No Intervention: Control

Detailed Description:

Tobacco smoking is the leading cause of preventable death. Considerable public health efforts are ongoing Canada-wide to reduce the prevalence of smoking in the general population. From 1985 to 2005, smoking rates among adults reduced from 35% to 19%. However, since that time, this steady rate of decline plateaued at around 18-19%. What else can be done to continue to significantly reduce the number of smokers at the population level? One option is to translate interventions that have demonstrated clinical efficacy into population level initiatives. Nicotine Replacement Therapy (NRT) has a considerable research base demonstrating its efficacy. Public health initiatives are underway to distribute NRT widely through mass distribution efforts. For example, over 58,000 NRT treatments have been distributed in the province of Ontario alone, and other provinces in Canada are considering adopting mass distribution procedures. However, one important question remains unanswered - do smoking cessation programs that involve mass distribution of free NRT work? Preliminary evidence consisting of before-after smoking status data from participants of mass NRT campaigns yielded promising results. However, such data cannot be used to make causal statements about the impact of NRT distribution. To answer this question, a randomized controlled trial is required.

A single blinded, panel survey design with random assignment to an experimental and a control condition will be used in this study. A two-stage recruitment process will be employed, in the context of a general population survey with two follow-ups (8 weeks and 6 months). Random digit dialing of Canadian home telephone numbers will identify households with adult smokers who are willing to take part in a smoking study that involves three interviews, with saliva collection for 3-HC/cotinine ratio measurement at baseline and saliva cotinine verification at 8-week and 6-month follow-ups.

As part of the baseline survey, eligible subjects will be identified for the second recruitment - randomization of smokers into experimental and control conditions to receive versus not receive nicotine patches. Eligibility will be determined by a series of questions regarding hypothetical interest in nicotine patches to quit smoking (including willingness to have nicotine patches sent to their home) and having no contraindications for using NRT. A randomized half of the eligible subjects will be assigned to the experimental condition and asked for their permission to have nicotine patches sent to their home. Subjects will be followed-up at 8 weeks and 6 months. Subjects in the control condition will not be offered nicotine patches. Interviewers will be blind to subjects' condition because they will be using computer assisted telephone interviewing (CATI) technology and as the first parts of the 8-week and 6-month follow-ups are identical for experimental and control conditions, they will not know the intervention condition to which a subject belongs until questions specific to the use of NRT are asked near the end of the surveys (i.e., after the primary outcome measures are assessed).

The primary hypothesis is that subjects who receive nicotine patches at baseline will display significantly higher quit rates (as assessed by 30 day point prevalence of abstinence from tobacco) at 6-month follow-up as compared to subjects who do not receive nicotine patches at baseline.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age and older
  • Current daily smokers who smoke 10 or more cigarettes per day
  • Interested in being involved in a smoking study
  • Willing to be interviewed at baseline, 8 weeks and 6 months after
  • Willing to provide a saliva sample for cotinine analysis at each time point
  • Interest in using nicotine patch to quit smoking
  • Intent to use nicotine patch within one week of receiving it
  • Willing to have nicotine patch sent to their home

Exclusion Criteria:

  • Have a medical condition that would would make participation medically hazardous as determined by the list of contraindications for NRT outlined in the CPS and the NRT package insert
  • Pregnant, intending on becoming pregnant, or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01429129

Contacts
Contact: John Cunningham, PhD 416-535-8501 ext 34682 John_Cunningham@camh.net

Locations
Canada, Ontario
Centre for Addiction and Mental Health Recruiting
Toronto, Ontario, Canada, M5S 2S1
Sponsors and Collaborators
Centre for Addiction and Mental Health
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: John Cunningham, PhD Centre for Addiction and Mental Health
  More Information

No publications provided by Centre for Addiction and Mental Health

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: John Cunningham, Senior Scientist, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier: NCT01429129     History of Changes
Other Study ID Numbers: 029/2011
Study First Received: September 2, 2011
Last Updated: June 5, 2014
Health Authority: Canada: Canadian Institutes of Health Research

Keywords provided by Centre for Addiction and Mental Health:
Smoking
Nicotine
Nicotine Replacement Therapy
Nicotine Patch
Nicoderm
Mass Distribution
Tobacco Control
Randomized Controlled Trial

Additional relevant MeSH terms:
Nicotine
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 25, 2014